<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="306">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157165</url>
  </required_header>
  <id_info>
    <org_study_id>00001</org_study_id>
    <nct_id>NCT05157165</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma in Hospitalized COVID-19 Patients</brief_title>
  <official_title>Convalescent Plasma in Hospitalized COVID-19 Patients: a Single Center Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale di Mantova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale di Mantova</source>
  <brief_summary>
    <textblock>
      The study assesses the efficacy and safety of administration of hyperimmune plasma in&#xD;
      hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following&#xD;
      convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to&#xD;
      plasma infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
      Adult inpatients with a severe form of COVID-19 have been enrolled, with at least one of the&#xD;
      following inclusion criteria: 1) tachypnea with respiratory rate (RR) &gt; 30 breaths/min; 2)&#xD;
      oxygen saturation (SpO2) ≤ 93% at rest and in room air; 3) partial pressure of oxygen&#xD;
      (PaO2)/fraction of inspired oxygen (FiO2) ≤ 200 mmHg, 4) radiological picture and/or chest CT&#xD;
      scan showing signs of interstitial disease and/or rapid progression of lung involvement.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Overall mortality at 28 days after hospitalization&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Adverse reaction to plasma transfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>COVID-19</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients admitted for severe COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  participation in any other clinical trial of an experimental treatment for COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Massimo Franchini, MD</last_name>
    <phone>00390376201234</phone>
    <email>massimo.franchini@asst-mantova.it</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 10, 2021</study_first_submitted>
  <study_first_submitted_qc>December 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 10, 2021</last_update_submitted>
  <last_update_submitted_qc>December 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale di Mantova</investigator_affiliation>
    <investigator_full_name>Massimo Franchini</investigator_full_name>
    <investigator_title>Director Immunohematology and Transfusion Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

